<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01233843</url>
  </required_header>
  <id_info>
    <org_study_id>GORTEC 2007-02</org_study_id>
    <nct_id>NCT01233843</nct_id>
  </id_info>
  <brief_title>Chemoradiotherapy HNSCC, Randomized Study, Docetaxel,Cisplatin, 5FU,Erbitux.</brief_title>
  <acronym>2007/02</acronym>
  <official_title>A Phase III Randomized Multicenter Study,Comparing an Induction Chemotherapy Followed by Irradiation and Concurrent Erbitux Versus Chemoradiotherapy for Patients With Locoregional Advanced Head and Neck Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe Oncologie Radiotherapie Tete et Cou</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Groupe Oncologie Radiotherapie Tete et Cou</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate that induction chemotherapy followed by radiation
      therapy plus Cetuximab will give better results than the validated treatment
      (chemoradiotherapy), for treatment of locoregional advanced head and neck cancers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Concurrent chemoradiotherapy (radiotherapy+ carboplatin + 5FU) is a validated treatment for
      patients with locoregional advanced head and neck cancers.

      This study evaluates the outcome of induction chemotherapy (docetaxel, cisplatin, 5 FU)
      followed by radiation therapy + Erbitux for patients with head and neck carcinoma with almost
      one measurable lesion by RMI or CT scan.

      We hope we can improve the progression free survival of 14% at two years .
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete response rate of the treatment</measure>
    <time_frame>by CT scan or MRI and endoscopy 2 years after the end of treatment</time_frame>
    <description>measure of the tumor</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The second focus of this study is to compare Overall survival between the two arms . It is defined as the time from the date of randomization to the date of death from any cause.</measure>
    <time_frame>Date of death</time_frame>
    <description>Aftercare every six months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">370</enrollment>
  <condition>Squamous Cell Head and Neck Carcinoma</condition>
  <arm_group>
    <arm_group_label>Drug and radiation</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Radiotherapy : 70 grays , fractionization : 2Gy/day, 5 days / week, for 7 weeks . Concurrent administration of Carboplatin: 70 mg/m2/day (day 1 until day 4)and 5FU 600 mg/m2/day (day 1 until day 4). Weeks 1; 4; 7.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>drug and radiation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction chemotherapy by Docetaxel 100mg/m2, day 1; cisplatin 100mg/m2, day 1; 5-Fluorouracil 1000mg/m2 (from day 1 to day 5), for a total of three cycles .Those cycles are administrated at day 1; day 22, day43.
This induction chemotherapy is followed ( for responders or stable disease patients)by radiotherapy (70 grays for 7 weeks) and concurrent Erbitux( weekly administration).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <description>70 mg per m2 and per day for four days. day 1; day 22; day 43</description>
    <arm_group_label>Drug and radiation</arm_group_label>
    <arm_group_label>drug and radiation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5 fluorouracil</intervention_name>
    <description>600mg per m2 per day for four days. 3 cycles day 1; day 22; day 43</description>
    <arm_group_label>Drug and radiation</arm_group_label>
    <arm_group_label>drug and radiation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <description>total dose: 70 grays. The patient receives 2 grays per day; five days a week during 7 weeks</description>
    <arm_group_label>Drug and radiation</arm_group_label>
    <arm_group_label>drug and radiation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  head and neck locally advanced,non metastatic carcinoma

          -  not suitable for surgery

        Exclusion Criteria:

          -  non squamous cell head and neck cancer

          -  previous malignancy

          -  previous treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lionnel GEOFFROIS, oncologist</last_name>
    <role>Study Director</role>
    <affiliation>Centre Alexis Vautrin NANCY France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Etienne BARDET, oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Rene Gauducheau NANTES France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christian SIRE, oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital de Bretagne Sud LORIENT France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laurent MARTIN, oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Guillaume le Conquerant LE HAVRE France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Marc TOURANI, oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU POITIERS France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philippe MAINGON, oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Georges Francois Leclerc</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ayman ZAWADI, oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHD de Vendee LA ROCHE SUR YON France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>François GUICHARD, oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Polyclinique de BORDEAUX NORD France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anne-Françoise DILLIES, oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Jean Perrin CLERMONT FERRAND France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dominique De RAUCOURT, oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre François Baclesse CAEN France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Emmanuel BABIN, oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital Cote de Nacre CAEN France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Claude TUCHAIS, oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Paul Papin ANGERS France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>XU SHAN Sun, oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital Emile Muller MULHOUSE France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nicolas MEERT, oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Grand Hôpital de Charleroi Belgique</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anne-Rose HENRY, oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU André Vésale MONTIGNY Belgique</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cedrik LAFOND, oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Jean Bernard LE MANS France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thierry PIGNON, oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Saint Louis TOULON France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ali HASBINI, oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinique Armoricaine SAINT BRIEUC France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean BOURHIS, oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Gustave Roussy VILLEJUIF France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marie SALIOU, oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Etienne Dolet SAINT NAZAIRE France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexandre COUTTE, oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU sud AMIENS France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GIRARD CALAIS Marie-Helene</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 25, 2010</study_first_submitted>
  <study_first_submitted_qc>November 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2010</study_first_posted>
  <last_update_submitted>October 25, 2017</last_update_submitted>
  <last_update_submitted_qc>October 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>induction chemotherapy</keyword>
  <keyword>followed by irradiation and concurrent Erbitux, or radiochemotherapy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

